Starling Oncology (STLNW) Total Current Liabilities (2019 - 2026)

Starling Oncology (STLNW) has reported Total Current Liabilities for 8 consecutive years, with $94.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Current Liabilities rose 46.56% year-over-year to $94.9 million; the trailing twelve-month figure through Jun 2026 stood at $94.9 million (up 46.56% YoY), and the FY2025 full-year result was $71.0 million, up 35.9% from the prior year.
• Total Current Liabilities rose to $94.9 million in Q2 2026 per STLNW's latest filing, from $79.4 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $94.9 million in Q2 2026 and bottomed at $29.7 million in Q4 2022.
• Historically, Total Current Liabilities has averaged $48.7 million across 5 years, with a median of $40.9 million in 2022.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 18271.88% in 2022, then dropped 7.26% in 2023.
• Over 5 years, Total Current Liabilities stood at $29.7 million in 2022, then grew by 17.05% to $34.8 million in 2023, then soared by 50.09% to $52.2 million in 2024, then jumped by 35.9% to $71.0 million in 2025, then jumped by 33.79% to $94.9 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $94.9 million, $79.4 million, and $71.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.